|
Sign In to gain access to subscriptions and/or personal tools.
|
Treatment of Chronic Nonvalvular Atrial Fibrillation in the Elderly
A Decision Analysis
I. Gary Naglie
Allan S. Detsky
The objective of the study was to determine the preferred treatment strategy for elderly patients with chronic nonvalvular atrial fibrillation (CNVAF). A Markov decision-analytic model was used to compare three treatment strategies for CNVAF: 1) warfarin; 2) aspirin; and 3) no treatment. Five-year quality-adjusted life years (QALYs) were calculated for male and female cohorts aged 70 and 75 years. In the baseline analysis (effectiveness of warfarin = 0.70, effectiveness of aspirin = 0.45, utility of warfarin = 0.99, and utility of aspirin = 0.999) the quality-adjusted survival rates for 70-year-old males were 4.03 QALYs on warfarin, 4.02 QALYs on aspirin, and 3.95 QALYs on no treatment. Results were similar for all age and sex cohorts. Sensitivity analyses revealed that the results were very sensitive to the effec tiveness of aspirin and the disutility of warfarin. The authors conclude that the optimal strategy for the treatment of CNVAF in elderly patients varies with the disutility assigned to warfarin therapy and the effectiveness value for aspirin therapy. Key words: chronic atrial fibrillation; elderly; anticoagulation; warfarin; aspirin; decision analysis; Markov analysis; quality of life. (Med Decis Making 1992;12:239-249)
Medical Decision Making, Vol. 12, No. 4,
239-249 (1992)
DOI: 10.1177/0272989X9201200401
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. P. Greving, E. Buskens, H. Koffijberg, and A. Algra
Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk
Circulation,
June 3, 2008;
117(22):
2875 - 2883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L Garwood and T. L Corbett
Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls
Ann. Pharmacother.,
April 1, 2008;
42(4):
523 - 532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Chan, B. K. Nallamothu, H. S. Gurm, R. A. Hayward, and S. Vijan
Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease
Circulation,
May 8, 2007;
115(18):
2398 - 2409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pignone, S. Earnshaw, M. J. Pletcher, and J. A. Tice
Aspirin for the Primary Prevention of Cardiovascular Disease in Women: A Cost-Utility Analysis
Arch Intern Med,
February 12, 2007;
167(3):
290 - 295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Chan, S. Vijan, F. Morady, and H. Oral
Cost-Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation
J. Am. Coll. Cardiol.,
June 20, 2006;
47(12):
2513 - 2520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pignone, S. Earnshaw, J. A. Tice, and M. J. Pletcher
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Ann Intern Med,
March 7, 2006;
144(5):
326 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Welton and A. E. Ades
Estimation of Markov Chain Transition Probabilities and Rates from Fully and Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration
Med Decis Making,
November 1, 2005;
25(6):
633 - 645.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Hur, N. S. Nishioka, and G. S. Gazelle
Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus
J Natl Cancer Inst,
February 18, 2004;
96(4):
316 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Eckman, S. K. Singh, J. K. Erban, and G. Kao
Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness Analysis
Med Decis Making,
April 1, 2002;
22(2):
108 - 124.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Catherwood, W. D. Fitzpatrick, M. L. Greenberg, P. T. Holzberger, D. J. Malenka, B. R. Gerling, and J. D. Birkmeyer
Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation
Ann Intern Med,
April 20, 1999;
130(8):
625 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Shlipak, W. L. Lyons, A. S. Go, T. M. Chou, G. T. Evans, and W. S. Browner
Should the Electrocardiogram Be Used to Guide Therapy for Patients With Left Bundle-Branch Block and Suspected Myocardial Infarction?
JAMA,
February 24, 1999;
281(8):
714 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Detsky, G. Naglie, M. D. Krahn, D. Naimark, and D. A. Redelmeier
Primer on Medical Decision Analysis: Part 1--Getting Started
Med Decis Making,
April 1, 1997;
17(2):
123 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Ackermann
Anticoagulant Therapy in Patients Aged 80 Years or More With Atrial Fibrillation: More Caution Is Needed
Arch Fam Med,
March 1, 1997;
6(2):
105 - 110.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. F. Gage, A. B. Cardinalli, and D. K. Owens
The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life
Arch Intern Med,
September 9, 1996;
156(16):
1829 - 1836.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. F. Gage, A. B. Cardinalli, G. W. Albers, and D. K. Owens
Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation
JAMA,
December 20, 1995;
274(23):
1839 - 1845.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. H. Eckman, S. Greenfield, W. C. Mackey, J. B. Wong, S. Kaplan, L. Sullivan, K. Dukes, and S. G. Pauker
Foot Infections in Diabetic Patients: Decision and Cost-effectiveness Analyses
JAMA,
March 1, 1995;
273(9):
712 - 720.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. R. Beck
Making Medical Decision Making More User-friendly
Med Decis Making,
February 1, 1993;
13(1):
1 - 2.
[PDF]
|
|
|
|
|
